OncoMatch/Clinical Trials/NCT03418038
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Is NCT03418038 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for clonal cytopenia of undetermined significance.
Treatment: Carboplatin · Cisplatin · Cytarabine · Dexamethasone · Etoposide · Gemcitabine Hydrochloride · Ifosfamide · Oxaliplatin · Rituximab · Decitabine — This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma
Acute Myeloid Leukemia
Biomarker criteria
Required: MYC rearrangement
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Required: BCL2 rearrangement
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Required: BCL6 rearrangement
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Required: TET2 mutation
CCUS with one or more TET2 mutations
Required: TET2 mutation with concurrent splicing gene mutation
TET2 mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2)
Required: SRSF2 mutation
splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2)
Required: U2AF1 mutation
splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2)
Required: SF3B1 mutation
splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2)
Required: ZRSR2 mutation
splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2)
Required: DNMT3A mutation
epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2)
Required: EZH2 mutation
epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2)
Required: IDH1 mutation
epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2)
Required: IDH2 mutation
epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2)
Required: TET2 mutation
chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation
Required: IDH1 mutation
chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation
Required: IDH2 mutation
chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: salvage therapy
no prior salvage therapy
Cannot have received: same platinum-based regimen
Exception: must not have received the same regimen in the past without responding
must not have received the same regimen in the past without responding
Cannot have received: CMML directed therapy
Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. Prior exposure to hydroxyurea is allowed.
No prior CMML directed therapy. Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. Prior exposure to hydroxyurea is allowed.
Cannot have received: any therapy
Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion. Exception: Palliative radiation is allowed
Any therapy ≤ 2 weeks prior to registration
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL (may transfuse to meet this requirement); ANC ≥ 1500/mm^3; Platelet count ≥ 75000/mm^3
Kidney function
Creatinine ≤ 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be ≥ 55 ml/min using the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 2 x ULN (if > 2 x ULN direct bilirubin is required and should be ≤ 1.5 x ULN); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)
Hemoglobin ≥ 8.0 g/dL (may transfuse to meet this requirement), obtained ≤ 14 days prior to registration; ANC ≥ 1500/mm^3, obtained ≤ 14 days prior to registration; Platelet count ≥ 75000/mm^3, obtained ≤ 14 days prior to registration; Total bilirubin ≤ 2 x ULN (if > 2 x ULN direct bilirubin is required and should be ≤ 1.5 x ULN), obtained ≤ 14 days prior to registration; ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement), obtained ≤ 14 days prior to registration; Creatinine ≤ 1.6 mg/dL; if over 1.6 then the calculated creatinine clearance must be ≥ 55 ml/min using the Cockcroft-Gault formula, obtained ≤ 7 days prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Health Systems-Mankato · Mankato, Minnesota
- Mayo Clinic in Rochester · Rochester, Minnesota
- Mayo Clinic Health System-Eau Claire Clinic · Eau Claire, Wisconsin
- Mayo Clinic Health System-Franciscan Healthcare · La Crosse, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify